Diagnosis, treatment, and prevention of Lyme disease in children

Pediatric Drugs

Volumn 5, Issue 6, 2003, Pages 363-372

  Eppes, Stephen C ^a,b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LYME DISEASE VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; OUTER SURFACE PROTEIN A VACCINE; PENICILLIN G; PROBENECID; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ARTHRITIS; BORRELIA BURGDORFERI; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG CHOICE; DRUG COST; DRUG HALF LIFE; DRUG INDUCED DISEASE; ENZYME IMMUNOASSAY; ESOPHAGUS ULCER; FACIAL NERVE PARALYSIS; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; LABORATORY DIAGNOSIS; LYME DISEASE; PHOTOSENSITIVITY DISORDER; PHYSICAL EXAMINATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SERODIAGNOSIS; TICK; TICK BITE; TOOTH COLOR; TOOTH DISEASE; TREATMENT OUTCOME; VACCINATION; WESTERN BLOTTING;

EID: 0038199774     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305060-00002     Document Type: Review

References (57)

1. Centers for Disease Control and Prevention. Demographic differences in notifiable infectious disease morbidity: United States, 1992-1994. MMWR Morb Mortal Wkly Rep 1997; 46: 637-41
2. Steere AC Medical progress: Lyme disease. New Engl J Med 2001; 345: 115-25
3. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep 1995; 44: 590-1
4. Liang FT. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi visE. J Clin Microbiol 1999; 37 (12): 3990-6
5. Hilton E, Tramontano A, Devoti J, et al. Temporal study of immunoglobin M seroreactivitiy to Borrelia burgdorferi in patients treated for Lyme borreliosis. J Clin Microbiol 1997; 35: 774-6
6. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface protein A with adjuvant. N Engl J Med 1998; 339: 209-15
7. Fahrer H, van der Linden SM, Sauvain MJ, et al. The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. J Infect Dis 1991; 163: 305-10
8. Klempner MS, Schmid CH, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med 2001; 110: 217-9
9. Nocton JJ, Dressler F, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330 (4): 229-34
10. Schmidt B, Muellegger RR, Stockenhuber C, et al. Detection of Borrelia burgdorferi-specific DNA in urine specimens from patients with erythema migrans before and after antibacterial therapy. J Clin Microbiol 1996; 34: 1359-63
11. Levin JM, Nelson JA, Segreti J, et al. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother 1993; 37: 1444-6
12. Dever LL, Jorgenson JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993; 37: 1704-6
13. Johnson RC, Kodner CB, Jurkovich PJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 2133-6
14. Kucers A, Bennett NMcK. editors. The use of antibacterials: a comprehensive review with clinical emphasis. 4th ed. Philadelphia (PA): JB Lippincott Company, 1987
15. Karlsson M, Hammers-Berggren S, Lindquist L, et al. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994; 44: 1203-7
16. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999; 28: 569-74
17. Dattwyler RJ, Luft BJ, Kunkel M, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997; 337: 289-94
18. Donta ST. Tetracycline therapy for chronic Lyme disease. Clin Infect Dis 1997 Jul; 25 Suppl. 1: S52-6
19. Lochary ME, Lockhart PB, Williams Jr WT. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998; 17: 429-30
20. Dattwyler RJ, Volkman DJ, Conaty SM, et al. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990; 336: 1404-6
21. Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878-88
22. Eppes SC, Childs JA. Comparative study of cefuroxime axetil vs amoxicillin in children with early Lyme disease. Pediatrics 2002; 109: 1173-7
23. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39: 661-7
24. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117: 273-80
25. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of early manifestations of Lyme disease. Ann Intern Med 1983; 99: 22-6
26. Dattwyler RJ, Grunwaldt E, Luft BJ. Clarithromycin in treatment of early Lyme disease: a pilot study. Antimicrob Agents Chemother 1996; 40: 468-9
27. Massorotti EM, Rahn DW, Messner RP, et al. Treatment of early Lyme disease. Am J Med 1992; 92: 396-403
28. Strle F, Preac-Mursic V, Cimperman J, et al. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiologic findings. Infection 1993; 21: 13-8
29. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-91
30. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995; 171: 356-61
31. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000; 31 Suppl. 1: S1-14
32. Cook SP, Macartney KK, Rose CD, et al. Lyme disease and seventh nerve paralysis in children. Am J Otolaryngol 1997; 18: 320-3
33. Luft BJ, Steinman CR, Neimark HC, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA 1992; 267: 1364-7
34. Belman AL, Reynolds L, Preston T, et al. Cerebrospinal fluid findings in children with Lyme disease-associated facial nerve palsy. Arch Pediatr Adolesc Med 1997; 151: 1224-8
35. Niemann G, Köksal MA, Oberle A, et al. Facial palsy and Lyme borreliosis: long-term follow-up of children with antibacterially untreated "idiopathic" facial palsy. Klin Pediatr 1997; 209: 95-9
36. Dattwyler RJ, Halperin JJ, Volkman DJ, et al. Treatment of late Lyme borreliosis: randomized comparison of ceftriaxone and penicillin. Lancet 1988; I: 1191-4
37. Eppes SC, Klein JD, Caputo G, et al. Physician beliefs, attitudes and approaches toward Lyme disease in an endemic area. Clin Pediatr 1994; 33: 130-4
38. Peña CA, Mathews AA, Siddiqi NH, et al. Antibacterial therapy for Lyme disease in a population-based cohort. Clin Infect Dis 1999; 29: 694-5
39. Preac-Mursic V, Weber K, Pfister HW, et al. Survival of Borrelia burgdorferi in antibacterially treated patients with Lyme borreliosis. Infection 1989; 17: 355-9
40. Pfister HW, Preac-Mursic V, Wilske B, et al. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis: a prospective randomized study. Arch Neurol 1989; 46: 1190-4
41. Pfister HW, Preac-Mursic V, Wilske B, et al. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991; 163: 311-8
42. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibacterial treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92
43. Salazar JC, Gerber MA, Goff CW. Long-term outcome of Lyme disease in children given early treatment. J Pediatr 1993; 122: 591-3
44. Adams WV, Rose CD, Eppes SC, et al. Cognitive effects of Lyme disease in children. Pediatrics 1994; 94: 185-9
45. Elliott DJ, Eppes SC, Klein JD. Teratagen update: Lyme disease. Teratology 2001; 64: 276-81
46. Schoen RT, Aversa JM, Rahn DW, et al. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991; 34: 1056-60
47. Eckman MH, Steere AC, Kalish RA, et al. Cost effectiveness of oral as compared with intravenous antibacterial therapy for patients with Lyme arthritis. N Engl J Med 1997; 337: 357-63
48. Nichol G, Dennis DT, Steere AC, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1998; 128: 37-48
49. Klein JD, Eppes SC, Hunt P. Environmental and lifestyle risk factors for Lyme disease in children. Clin Pediatr 1996; 35: 359-63
50. Shapiro ED, Gerber MA, Holabird ND, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease following deer-tick bites. N Engl J Med 1992; 327: 1769-73
51. Warshafsky S, Nowakowski J, Nadelman RB, et al. Efficacy of antibacterial prophylaxis for prevention of Lyme disease. J Gen Intern Med 1996; 11: 329-33
52. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79-84
53. Magid D, Schwartz B, Craft J, et al. Prevention of Lyme disease after tick bites: a cost effectiveness analysis. N Engl J Med 1992; 327: 534-41
54. Shapiro ED. Doxycycline for tick bites: not for everyone. N Engl J Med 2001; 345: 133-4
55. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998; 339: 216-22
56. Halsey NA, Sikand VK, Van Hoecke C, et al. Safety and immunogenicity of LYMErix, Lyme disease vaccine (recombinant ospA) in children 4-18 years [abstract]. Pediatr Res 2000; 47: 263A
57. Malloy PJ, Berardi VP, Persing DH, et al. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A Lyme disease vaccination. Clin Infect Dis 2000; 31: 42-7